NCT06237881 2026-02-18A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid TumorsM.D. Anderson Cancer CenterPhase 1/2 Active not recruiting15 enrolled
NCT03474497 2026-01-29UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint BlockadeUniversity of California, DavisPhase 1/2 Active not recruiting18 enrolled 13 charts
NCT05194735 2025-11-10Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid TumorsAlaunos TherapeuticsPhase 1/2 Terminated8 enrolled 12 charts
NCT05296564 2025-10-02Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic CancersHadassah Medical OrganizationPhase 1/2 Recruiting3 enrolled